Filing Flows › Mangoceuticals (MGRX) › Q1 2026 › vs Q1 2025
Mangoceuticals (MGRX) Q1 2026 vs Q1 2025 (year over year)
Mangoceuticals's revenue fell $41K (-38%) from $109K in Q1 2025 to $68K in Q1 2026.
Mangoceuticals, Q1 2026: revenue $68K (-38% year over year), net loss $3.4M, operating cash flow −$1.3M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $68K | $109K | −$41K | -38% |
| Net loss | $3.4M | $4.8M | −$1.4M | -30% |
| Costs & expenses | $3.5M | $4.9M | −$1.5M | -30% |
| Operating costs | $3.2M | $4.7M | −$1.5M | -32% |
| Interest & other, net | $277K | $263K | $14K | +5% |
| Cost of revenue | $39K | $47K | −$8K | -18% |
| Sales & marketing | $94K | $282K | −$188K | -67% |
| General & admin | $1.1M | $1.5M | −$488K | -32% |
| Other operating costs | $2.0M | $2.8M | −$807K | -29% |
| Operating cash sources | $3.4M | $4.8M | −$1.4M | -30% |
| Depreciation & amortization | $277K | $277K | $0 | 0% |
| Share-based compensation | $1.1M | $51K | $1.0M | 21× |
| Working capital & other | $725K | $2.2M | −$1.5M | -68% |
| Cash used in operations | $1.3M | $2.3M | −$963K | -42% |
| Net loss absorbed | $3.4M | $4.8M | −$1.4M | -30% |
Questions
How much did Mangoceuticals's revenue grow year over year in Q1 2026?
Mangoceuticals's revenue fell $41K (-38%) from $109K in Q1 2025 to $68K in Q1 2026.